Compare Sanofi SA (SNY) vs Tesla, Inc. (TSLA) Price & Performance

Sanofi SATrade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Tesla, Inc. — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Tesla, Inc. trades at $379.45 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 13.3× Sanofi SA's market cap, and Sanofi SA pays a 5.5% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.

	SNY	TSLA
Market Cap	$104.83B	$1.39T
Sector	Health	Consumer Cyclical
52-Week High	$52.34	$489.88
52-Week Low	$41.33	$302.63
Enterprise Value	$121.32B	$1.36T
Dividend Yield	5.5%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $378.88, down 0.51% on the day, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with revenue declining to $94.83B in 2025 and net income margin compressing to 3.95%, while valuation multiples remain elevated with a P/E of 339.06. Recent news highlights Tesla's strategic pivot toward robotics, AI, and energy growth amid a slowing auto business, with regulatory approval for driver-assistance software in Europe providing a potential catalyst.

Tesla's investment case balances high-growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 suggests modest upside, but investors face headwinds from competitive pressures and margin compression. The stock's trajectory will likely hinge on successful commercialization of new technologies and improved automotive profitability.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SNY

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026GlobeNewsWire · 9 hours agoNeutral View details →

TSLA

Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 5 hours agoNeutral Northrop Grumman CEO hints space robots could be weaponized, leaving decision to US government.Forbes · 5 hours agoBullish Options traders expect Tesla's biggest post-earnings move in a year, with a 5.76% price swing implied.CNBC · 6 hours agoNeutral View details →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.